Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas

Eirwen M. Miller, Joan Tymon-Rosario, Jaya Sunkara, Bryan E. Harmon, Rouzan G. Karabakhtsian, Akiva P. Novetsky

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Diagnosis of endometrial clear cell carcinomas is difficult owing to the low reproducibility of histological cell type in high-grade endometrial cancers. Recently, immunoreactivity for napsin A and glypican 3 has been reported in clear cell cancers. We sought to evaluate the use of napsin A and glypican 3 staining to distinguish clear cell carcinoma from other high-grade endometrial cancers. Methods/Materials Twenty cases of pure and mixed endometrial clear cell carcinoma were extracted from the 2000-2014 archival material in the Departments of Obstetrics & Gynecology and Pathology at Montefiore Medical Center and compared to serous and grade 3 endometrioid controls. Representative sections were stained with monoclonal antibodies to napsin A and glypican 3. Immunostains were independently reviewed by 2 pathologists to assess frequency and pattern of staining. Charts were reviewed for clinicopathologic and treatment data. Results Granular cytoplasmic positivity for napsin A was observed in 70% of endometrial clear cell carcinomas; only 25% showed cytoplasmic or membranous glypican 3 positivity. No serous or high-grade endometrioid tumors stained for either marker. No cases of clear cell carcinoma that stained negative for napsin A stained positive for glypican 3. No difference in the immunohistochemical profile was found between pure and mixed clear cell carcinomas and between early- and advanced-stage clear cell carcinomas. Conclusions Napsin A is a more sensitive marker for endometrial clear cell carcinoma than glypican 3. In histologically ambiguous cases, napsin A and glypican 3 may help distinguish clear cell carcinoma from other high-grade histologies. Further investigation of endometrial clear cell carcinoma is needed to identify additional diagnostic tools for this rare histology. Correlation of a unique immunohistochemical profile and clinical outcomes is necessary.

Original languageEnglish (US)
Pages (from-to)1318-1324
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume28
Issue number7
DOIs
StatePublished - Sep 1 2018

Fingerprint

Glypicans
Endometrioid Carcinoma
Carcinoma
Endometrial Neoplasms
Histology
Staining and Labeling
Hospital Obstetrics and Gynecology Department
Gynecology

Keywords

  • Clear cell carcinoma
  • Glypican 3
  • High-grade endometrial cancer
  • Immunohistochemistry
  • Napsin A

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas. / Miller, Eirwen M.; Tymon-Rosario, Joan; Sunkara, Jaya; Harmon, Bryan E.; Karabakhtsian, Rouzan G.; Novetsky, Akiva P.

In: International Journal of Gynecological Cancer, Vol. 28, No. 7, 01.09.2018, p. 1318-1324.

Research output: Contribution to journalArticle

@article{78d6d7461e564bfaa780a15c3bd5ca55,
title = "Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas",
abstract = "Diagnosis of endometrial clear cell carcinomas is difficult owing to the low reproducibility of histological cell type in high-grade endometrial cancers. Recently, immunoreactivity for napsin A and glypican 3 has been reported in clear cell cancers. We sought to evaluate the use of napsin A and glypican 3 staining to distinguish clear cell carcinoma from other high-grade endometrial cancers. Methods/Materials Twenty cases of pure and mixed endometrial clear cell carcinoma were extracted from the 2000-2014 archival material in the Departments of Obstetrics & Gynecology and Pathology at Montefiore Medical Center and compared to serous and grade 3 endometrioid controls. Representative sections were stained with monoclonal antibodies to napsin A and glypican 3. Immunostains were independently reviewed by 2 pathologists to assess frequency and pattern of staining. Charts were reviewed for clinicopathologic and treatment data. Results Granular cytoplasmic positivity for napsin A was observed in 70{\%} of endometrial clear cell carcinomas; only 25{\%} showed cytoplasmic or membranous glypican 3 positivity. No serous or high-grade endometrioid tumors stained for either marker. No cases of clear cell carcinoma that stained negative for napsin A stained positive for glypican 3. No difference in the immunohistochemical profile was found between pure and mixed clear cell carcinomas and between early- and advanced-stage clear cell carcinomas. Conclusions Napsin A is a more sensitive marker for endometrial clear cell carcinoma than glypican 3. In histologically ambiguous cases, napsin A and glypican 3 may help distinguish clear cell carcinoma from other high-grade histologies. Further investigation of endometrial clear cell carcinoma is needed to identify additional diagnostic tools for this rare histology. Correlation of a unique immunohistochemical profile and clinical outcomes is necessary.",
keywords = "Clear cell carcinoma, Glypican 3, High-grade endometrial cancer, Immunohistochemistry, Napsin A",
author = "Miller, {Eirwen M.} and Joan Tymon-Rosario and Jaya Sunkara and Harmon, {Bryan E.} and Karabakhtsian, {Rouzan G.} and Novetsky, {Akiva P.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1097/IGC.0000000000001303",
language = "English (US)",
volume = "28",
pages = "1318--1324",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas

AU - Miller, Eirwen M.

AU - Tymon-Rosario, Joan

AU - Sunkara, Jaya

AU - Harmon, Bryan E.

AU - Karabakhtsian, Rouzan G.

AU - Novetsky, Akiva P.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Diagnosis of endometrial clear cell carcinomas is difficult owing to the low reproducibility of histological cell type in high-grade endometrial cancers. Recently, immunoreactivity for napsin A and glypican 3 has been reported in clear cell cancers. We sought to evaluate the use of napsin A and glypican 3 staining to distinguish clear cell carcinoma from other high-grade endometrial cancers. Methods/Materials Twenty cases of pure and mixed endometrial clear cell carcinoma were extracted from the 2000-2014 archival material in the Departments of Obstetrics & Gynecology and Pathology at Montefiore Medical Center and compared to serous and grade 3 endometrioid controls. Representative sections were stained with monoclonal antibodies to napsin A and glypican 3. Immunostains were independently reviewed by 2 pathologists to assess frequency and pattern of staining. Charts were reviewed for clinicopathologic and treatment data. Results Granular cytoplasmic positivity for napsin A was observed in 70% of endometrial clear cell carcinomas; only 25% showed cytoplasmic or membranous glypican 3 positivity. No serous or high-grade endometrioid tumors stained for either marker. No cases of clear cell carcinoma that stained negative for napsin A stained positive for glypican 3. No difference in the immunohistochemical profile was found between pure and mixed clear cell carcinomas and between early- and advanced-stage clear cell carcinomas. Conclusions Napsin A is a more sensitive marker for endometrial clear cell carcinoma than glypican 3. In histologically ambiguous cases, napsin A and glypican 3 may help distinguish clear cell carcinoma from other high-grade histologies. Further investigation of endometrial clear cell carcinoma is needed to identify additional diagnostic tools for this rare histology. Correlation of a unique immunohistochemical profile and clinical outcomes is necessary.

AB - Diagnosis of endometrial clear cell carcinomas is difficult owing to the low reproducibility of histological cell type in high-grade endometrial cancers. Recently, immunoreactivity for napsin A and glypican 3 has been reported in clear cell cancers. We sought to evaluate the use of napsin A and glypican 3 staining to distinguish clear cell carcinoma from other high-grade endometrial cancers. Methods/Materials Twenty cases of pure and mixed endometrial clear cell carcinoma were extracted from the 2000-2014 archival material in the Departments of Obstetrics & Gynecology and Pathology at Montefiore Medical Center and compared to serous and grade 3 endometrioid controls. Representative sections were stained with monoclonal antibodies to napsin A and glypican 3. Immunostains were independently reviewed by 2 pathologists to assess frequency and pattern of staining. Charts were reviewed for clinicopathologic and treatment data. Results Granular cytoplasmic positivity for napsin A was observed in 70% of endometrial clear cell carcinomas; only 25% showed cytoplasmic or membranous glypican 3 positivity. No serous or high-grade endometrioid tumors stained for either marker. No cases of clear cell carcinoma that stained negative for napsin A stained positive for glypican 3. No difference in the immunohistochemical profile was found between pure and mixed clear cell carcinomas and between early- and advanced-stage clear cell carcinomas. Conclusions Napsin A is a more sensitive marker for endometrial clear cell carcinoma than glypican 3. In histologically ambiguous cases, napsin A and glypican 3 may help distinguish clear cell carcinoma from other high-grade histologies. Further investigation of endometrial clear cell carcinoma is needed to identify additional diagnostic tools for this rare histology. Correlation of a unique immunohistochemical profile and clinical outcomes is necessary.

KW - Clear cell carcinoma

KW - Glypican 3

KW - High-grade endometrial cancer

KW - Immunohistochemistry

KW - Napsin A

UR - http://www.scopus.com/inward/record.url?scp=85052682942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052682942&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000001303

DO - 10.1097/IGC.0000000000001303

M3 - Article

C2 - 30036224

AN - SCOPUS:85052682942

VL - 28

SP - 1318

EP - 1324

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 7

ER -